title: Patient-reported experience with Velosulin human insulin in continuous subcutaneous insulin infusion.
abstract: A multicenter, retrospective survey of 339 patients with insulin-dependent diabetes mellitus was done to evaluate patient experience with Velosulin Human insulin, a regular insulin in a phosphate buffer, used in continuous subcutaneous insulin infusion. Patients had used this insulin exclusively for 3 months preceding the survey. Responses were elicited through interviews conducted by physicians or nurses. Patients were queried as to the occurrence of specific complications associated with pump therapy that occurred while using Velosulin Human insulin, including hypoglycemia, diabetic ketoacidosis, unexplained hyperglycemia, tubing obstruction, and infection or abscess at the infusion site. Most patients reported that they did not experience any of these complications during the preceding 3 months. The most frequently cited complication was hyperglycemia unexplained by dosage, exercise, or dietary changes, reported by 110 (32%) patients. The second most frequently reported complication was tubing obstruction, reported by 99 (29%) patients. The reported frequencies of the other complications were: severe hypoglycemia, 45 (13%) patients; diabetic ketoacidosis, 28 (8%) patients; and infection or abscess at the infusion site, 26 (8%) patients. The low morbidity reported by the patients in this survey probably was due in large part to careful patient selection, a high level of motivation on the part of the patients, and experience and education on the part of the health care team, as well as to the use of buffered regular human insulin.
authors.affiliation: USC School of Medicine, Los Angeles, USA.
authors.forename: A
authors.initials: A
authors.lastname: Marcus
authors.forename: B
authors.initials: B
authors.lastname: Bode
authors.forename: A
authors.initials: A
authors.lastname: Drexler
authors.forename: E
authors.initials: E
authors.lastname: Etkind
authors.forename: M M
authors.initials: MM
authors.lastname: Koch
authors.forename: J E
authors.initials: JE
authors.lastname: Liljenquist
authors.forename: D K
authors.initials: DK
authors.lastname: McCulloch
authors.forename: S M
authors.initials: SM
authors.lastname: Strowig
authors.forename: R J
authors.initials: RJ
authors.lastname: Tanenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000209:etiology; D004868:Equipment Failure; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D007003:Hypoglycemia / Q000209:etiology; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007328:Insulin